Journal of global infectious diseases · 2025
Clinical Presentations and Species Spectrum of Nontuberculous Mycobacteria in Suspected Pulmonary Tuberculosis Cases.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Das Sivasankar, Mohapatra Prasanta Raghab, Rath Sutapa, Bhuniya Sourin, Mishra Baijayantimala
Аннотация
INTRODUCTION: The prevalence of nontuberculous mycobacteria (NTM) is on the rise worldwide. The diagnosis of NTM lung disease (NTM-LD) is a dilemma. The 2020 guidelines jointly established by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) outline the criteria for diagnosing pulmonary NTM disease. Herein, we report a series of cases with an analysis of relevant literature to gain insight into the pathogenicity of NTM species, the risk factors involved, and treatment strategies.
METHODS: This is a prospective observational study starting from April 2023 to December 2023. A total of 370 suspected pulmonary tuberculosis (TB) patients were included. Clinical specimens were processed for Ziehl-Neelsen staining, GeneXpert Mycobacterium tuberculosis (MTB)/RIF assay, and culture. Culture-positive mycobacteria were classified as MTB complex or NTM based on detection of MPT64 antigen. The NTM isolates were speciated by line probe assay using GenoType® Mycobacterium common mycobacteria (Hain Lifescience, Nehren, Germany). The criteria of ATS/IDSA were applied to confirm NTM-LD.
RESULTS: Nine (n = 9) patients were diagnosed as cases of NTM-LD. Bronchiectasis and previous TB were the most common comorbidities. Mycobacterium scrofulaceum (n = 2), Mycobacterium szulgai (n = 2), Mycobacterium intracellulare (n = 1), Mycobacterium kansasii (n = 1), Mycobacterium abscessus (n = 1), Mycobacterium fortuitum (n = 1), and Mycobacterium interjectum (n = 1) were the species involved. Specific therapeutic drug regimens were administered in four cases, which resulted in clinical improvement.
CONCLUSION: People with comorbid (LDs) are at risk of NTM-LD. The severity of NTM-LD and mortality also depend on the species involved. New guidelines with evidence-based recommendations should be formulated to simplify the diagnosis and treatment of NTM-LD caused by an array of more than 190 species.
METHODS: This is a prospective observational study starting from April 2023 to December 2023. A total of 370 suspected pulmonary tuberculosis (TB) patients were included. Clinical specimens were processed for Ziehl-Neelsen staining, GeneXpert Mycobacterium tuberculosis (MTB)/RIF assay, and culture. Culture-positive mycobacteria were classified as MTB complex or NTM based on detection of MPT64 antigen. The NTM isolates were speciated by line probe assay using GenoType® Mycobacterium common mycobacteria (Hain Lifescience, Nehren, Germany). The criteria of ATS/IDSA were applied to confirm NTM-LD.
RESULTS: Nine (n = 9) patients were diagnosed as cases of NTM-LD. Bronchiectasis and previous TB were the most common comorbidities. Mycobacterium scrofulaceum (n = 2), Mycobacterium szulgai (n = 2), Mycobacterium intracellulare (n = 1), Mycobacterium kansasii (n = 1), Mycobacterium abscessus (n = 1), Mycobacterium fortuitum (n = 1), and Mycobacterium interjectum (n = 1) were the species involved. Specific therapeutic drug regimens were administered in four cases, which resulted in clinical improvement.
CONCLUSION: People with comorbid (LDs) are at risk of NTM-LD. The severity of NTM-LD and mortality also depend on the species involved. New guidelines with evidence-based recommendations should be formulated to simplify the diagnosis and treatment of NTM-LD caused by an array of more than 190 species.